Parenteral Drugs (India) (NSE:PDPL) Other Current Receivables: ₹92.46 Mil (As of Mar. 2022)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) Other Current Receivables?

Parenteral Drugs (India) NSE:PDPL 4 Other Current Receivables is ₹92.46 Mil as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Parenteral Drugs (India)'s Other Current Receivables for the quarter that ended in Mar. 2022 was ₹92.46 Mil.

Parenteral Drugs (India)'s quarterly Other Current Receivables declined from Sep. 2021 (₹94.46 Mil) to Dec. 2021 (₹0.00 Mil) but then increased from Dec. 2021 (₹0.00 Mil) to Mar. 2022 (₹92.46 Mil).

Parenteral Drugs (India)'s annual Other Current Receivables declined from Mar. 2020 (₹656.07 Mil) to Mar. 2021 (₹655.73 Mil) and declined from Mar. 2021 (₹655.73 Mil) to Mar. 2022 (₹92.46 Mil).

Parenteral Drugs (India) Other Current Receivables Related Terms

Parenteral Drugs (India) Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Other Current Receivables Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 643.66 623.21 656.07 655.73 92.46

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 655.73 0.00 94.46 0.00 92.46
NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of ₹92.46 Mil mean?
Parenteral Drugs (India) (NSE:PDPL) has a Other Current Receivables of ₹92.46 Mil as of Mar. 2022. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Other Current Receivables too high?
Parenteral Drugs (India)'s current Other Current Receivables is ₹92.46 Mil. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Other Current Receivables compare to ZTS and CTLT?
Parenteral Drugs (India)'s Other Current Receivables of ₹92.46 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current Other Current Receivables is ₹92.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Other Current Receivables of ₹92.46 Mil. The current Other Current Receivables is ₹92.46 Mil. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Other Current Receivables is ₹92.46 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price